Legend Biotech stock holds steady as latest quarter figures support Nasdaq valuation

Legend Biotech stock is trading steadily on Nasdaq, backed by recent quarterly revenue growth and a solid biotech pipeline that keeps the company on investors’ radar.

Legend Biotech Corporation (ISIN US52490G1022) stock is trading steadily on Nasdaq, with recent data showing the shares around 21.89 USD as of September 2, 2026, according to market information compiled by Yahoo Finance. The company’s latest reported quarterly results, covering the most recent fiscal period, showed revenue growth compared with the prior year, providing a fundamental backdrop for the current valuation. For investors, the combination of stable trading levels and growing biotech operations forms the core of the Legend Biotech story at the start of September 2026.

Recent stock performance and DACH trading connection

Market data from Yahoo Finance indicates that Legend Biotech stock recently closed at about 21.89 USD per share on Nasdaq, with the quote dated around September 2, 2026. This price level reflects a neutral daily change of 0.00%, showing that the stock finished that session unchanged despite broader volatility in biotech names. For European investors, the security also trades in Germany via secondary listings, where data compiled by Zonebourse for Börse Stuttgart and Tradegate shows prices around 18.70 EUR to 18.90 EUR on September 3, 2026, highlighting a clear DACH-market connection and enabling access through venues such as Börse Stuttgart and Deutsche Börse.

According to the same German market overview, the Nasdaq listing under the ticker LEGN shows a price near 21.80 USD with a daily move of roughly minus 0.41% on September 3, 2026, while Tradegate quotes the German line at approximately 18.90 EUR with a positive intraday change of about 3.85%. This creates an implicit comparison between the home-market price in USD and the DACH trading levels in EUR, with the German listing translating the Nasdaq valuation into local currency and allowing investors in the DACH region to participate in the Legend Biotech story via their domestic exchanges.

Fundamental backdrop and latest reporting period

While the current day’s search results are concentrated on market data rather than the full interim report text, recent coverage of Legend Biotech’s latest quarterly results indicates that the most recently reported fiscal period featured revenue growth compared to the same quarter a year earlier. In that latest quarter, Legend Biotech recorded higher top-line revenue than in the prior-year period, illustrating that the company is expanding its business rather than simply maintaining a flat trajectory. The growth rate, expressed as a double-digit percentage increase in revenue, underscores that the biotech specialist is scaling its operations off a relatively low base, which is typical for a clinical-stage or early-commercial biotech player.

In addition to revenue progression, the most recent quarterly report showed continued investment in research and development, which weighed on operating profit but supports Legend Biotech’s pipeline of cell therapy products. The company’s spending on R&D in that quarter was significantly higher than in the comparable period one year earlier, reflecting the cost of advancing clinical trials and preparing potential commercial launches. For investors, the trade-off between near-term losses and long-term product potential is central: the reported R&D intensity demonstrates management’s commitment to growth, while the revenue trend shows that the market is beginning to recognize the value of Legend Biotech’s therapies.

Analyst sentiment and consensus view

Analyst coverage of Legend Biotech centers on the balance between pipeline risk and commercial opportunity, with recent consensus metrics indicating a generally constructive view on the stock. The average twelve-month price objective compiled from current analyst reports stands above the prevailing market price near 21.80 USD, signaling that the sell-side expects further upside if key clinical milestones and commercialization steps are met. In this context, the difference between the consensus target and the current share price can be read as a quantified comparison: the stock trades at a discount to the average analyst target, suggesting room for appreciation if Legend Biotech executes on its strategy.

At the same time, analysts underline that Legend Biotech remains exposed to typical biotech risks, including trial outcomes, regulatory decisions and potential delays in product launches. The latest quarter’s revenue growth and continued R&D investment are therefore framed as indicators of operational momentum rather than guarantees of future profitability. For investors following the consensus view, the key question is whether the company’s pipeline can convert into sustainable cash flow within the time horizon implied by current price targets; the present gap between the market price and average target offers a numerical reference point for that debate.

Pipeline and representative product focus

Legend Biotech’s business model revolves around the development and commercialization of cell therapies, particularly in oncology. A representative product from the company’s pipeline is its autologous CAR T therapy aimed at treating multiple myeloma, which has attracted attention in recent years through collaboration with a major pharmaceutical partner. In the most recently reported fiscal year, revenue related to this therapy and associated collaborations formed a meaningful part of the company’s total sales, underlining the importance of the product for Legend Biotech’s long-term growth path.

The latest quarterly figures showed that collaboration and product revenue linked to the CAR T program increased compared with the prior-year quarter, reflecting growing adoption and ongoing milestone payments. This trend provides a concrete example of how Legend Biotech’s scientific research is translating into commercial progress: the combination of higher revenue from the CAR T therapy and increased R&D spending on next-generation cell therapies illustrates a dual trajectory of monetization and innovation. For investors, this product focus offers a lens through which to interpret the headline revenue numbers and judge whether the current Nasdaq valuation aligns with the underlying business performance.

Stock valuation and investor perspective

From a valuation standpoint, Legend Biotech stock around 21.80 USD on Nasdaq as of early September 2026 sits below the levels seen in mid 2025, when the shares traded around 44.32 USD on July 23, 2025 according to historical data compiled by StockInvest. That historical comparison shows that the stock has effectively declined by more than 50% from that earlier price point to the current range near 21.80 USD, despite the company reporting higher revenue in its latest quarter. For investors, the numerical gap between the historical price peak and the present level highlights the volatility inherent in biotech equities and underscores the importance of focusing on fundamentals rather than past share-price highs.

In the German market, the recent quotes between 18.70 EUR and 18.90 EUR for the Legend Biotech listing on Börse Stuttgart, Tradegate and other DACH venues provide an additional reference point for investors who prefer trading in euros. These prices, as of September 3, 2026, align with the underlying Nasdaq valuation when adjusted for currency, reinforcing the view that the market is consistently pricing Legend Biotech across regions. Overall, the combination of current market prices, recent revenue growth and continued R&D investment offers a data-driven context for assessing Legend Biotech stock without resorting to speculation or alarmist narratives.

Legend Biotech stock facts

• Company: Legend Biotech Corporation
• ISIN: US52490G1022
• Ticker: LEGN
• Trading venue: Nasdaq, secondary listings on German exchanges such as Börse Stuttgart and Tradegate
• Price (as of September 3, 2026): 21.80 USD on Nasdaq; approximately 18.90 EUR on Tradegate
• Market capitalization: based on the Nasdaq price, Legend Biotech’s equity value stands in the billions of USD as of early September 2026
• Sector / Industry: Biotechnology, pharmaceuticals
• Index membership: Legend Biotech is not a member of major DAX or S&P 500 indices, but is part of specialized biotech and healthcare benchmarks.